¼¼°èÀÇ µðÁöÅÐ ¹é½Å ½ÃÀå
Digital Vaccines
»óǰÄÚµå : 1758172
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 274 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,160,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,480,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ µðÁöÅÐ ¹é½Å ½ÃÀåÀº 2030³â±îÁö 31¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 18¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ µðÁöÅÐ ¹é½Å ½ÃÀåÀº 2024-2030³â¿¡ CAGR 9.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ½º¸¶Æ®Æù µð¹ÙÀ̽º´Â CAGR 9.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 20¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÅÂºí¸´ ´Ü¸»±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 7.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 9,650¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ µðÁöÅÐ ¹é½Å ½ÃÀåÀº 2024³â¿¡ 4¾ï 9,650¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 12.7%·Î 2030³â±îÁö 6¾ï 2,780¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 6.5%¿Í 8.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 7.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ µðÁöÅÐ ¹é½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

µðÁöÅÐ ¹é½ÅÀ̶õ ¹«¾ùÀ̸ç, ¿Ö ¿¹¹æ ÀǷḦ ÀçÁ¤ÀÇÇØ¾ß Çϴ°¡?

µðÁöÅÐ ¹é½ÅÀº ¿¹¹æ ÀÇ·áÀÇ »õ·Î¿î ÆÐ·¯´ÙÀÓÀ» »ó¡ÇÕ´Ï´Ù. µðÁöÅÐ Ç÷§Æû°ú ½Å°æÀÎÁö ÈÆ·ÃÀ» Ȱ¿ëÇÏ¿© »ý¹°ÇÐÀû ¾à¹°ÀÌ ¾Æ´Ñ Çൿ Á¶°ÇÈ­¿Í ½Å°æÁ¶ÀýÀ» ÅëÇØ Çൿ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í, ȸº¹Åº·Â¼ºÀ» ³ôÀ̰í, Áúº´¿¡ ´ëÇÑ ¸é¿ª·ÂÀ» °­È­ÇÕ´Ï´Ù. µðÁöÅÐ ¹é½ÅÀº ½º¸¶Æ®Æù, ÅÂºí¸´, °¡»óÇö½Ç ½Ã½ºÅÛÀ» ÅëÇØ Á¦°øµÇ´Â ¼ÒÇÁÆ®¿þ¾î ±â¹Ý °³ÀÔÃ¥À¸·Î, ÇൿÀ» º¯È­½Ã۰í Á¤½ÅÀû, »ý¸®Àû ¹ÝÀÀ ÆÐÅÏÀ» °³¼±ÇÏ¿© ½ºÆ®·¹½º, ºÒ¾È, Áßµ¶ ¶Ç´Â °¨¿°°ú °°Àº Áõ»óÀ» ¿¹¹æÇϵµ·Ï ¼³°èµÈ ¼ÒÇÁÆ®¿þ¾î ±â¹Ý °³ÀÔÃ¥ÀÔ´Ï´Ù. ±¸Á¶È­µÈ ¿îµ¿¿¡ »ç¿ëÀÚ¸¦ Âü¿©½Ãŵ´Ï´Ù.

Ç׿øÀ» ÅëÇØ ¸é¿ª ¹ÝÀÀÀ» ÀÚ±ØÇÏ´Â ±âÁ¸ ¹é½Å°ú ´Þ¸®, µðÁöÅÐ ¹é½ÅÀº ³ú ȸ·Î¸¦ Ȱ¼ºÈ­ÇÏ¿© ½Å°æ°è¸¦ ÈÆ·Ã½ÃÄÑ Çൿ ¸é¿ª·ÂÀ» °­È­ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ƯÈ÷ Á¤½Å°Ç°­ Àå¾Ö, Çൿ Áßµ¶, »ýȰ½À°üº´¿¡ ´ëÇÑ ´ëó¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¾î¸°ÀÌÀÇ °æ¿ì, µðÁöÅÐ ¹é½ÅÀº »çȸ¼º ¹× Á¤¼­Àû ÇнÀ°ú ÀÎÁö ±â¼úÀ» ÃËÁøÇϰí, ºÒ¾È°ú µ¿·áÀÇ ¾Ð·ÂÀ¸·Î ÀÎÇÑ Çൿ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÁÙÀ̱â À§ÇØ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¼ºÀÎÀÇ °æ¿ì, ½ºÆ®·¹½º ¹ÝÀÀÀ» Á¶ÀýÇϰí, Èí¿¬°ú À½ÁÖ ½À°üÀ» ÁÙÀ̰í, ÀÎÁöÀû ȸº¹Åº·Â¼ºÀ» ÃËÁøÇϱâ À§ÇÑ ÅøÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù.

µðÁöÅÐ ¹é½Å Ç÷§ÆûÀÇ µîÀåÀ» ÃËÁøÇÏ´Â ±â¼úÀº ¹«¾ùÀΰ¡?

µðÁöÅÐ ¹é½ÅÀº ÀΰøÁö´É, °ÔÀ̹ÌÇÇÄÉÀ̼Ç, ½Å°æÇൿÇÐÀû ¾Ë°í¸®Áò, ÀûÀÀÇü ÇнÀ ¸ðµ¨ µî ´Ù¾çÇÑ ÀÎÁö ÄÄÇ»ÆÃ ±â¼ú¿¡ ÀÇÁ¸ÇÕ´Ï´Ù. ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ǵ ÁÖ¿ä Àü´Þ ÀÎÅÍÆäÀ̽º ¿ªÇÒÀ» Çϸç, AI´Â »ç¿ëÀÚÀÇ Çൿ µ¥ÀÌÅÍ¿Í ¼º´É ÆÐÅÏ¿¡ µû¶ó ÀÎÁö ÀÛ¾÷À» ¸ÂÃãÈ­ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ´º·ÎÇǵå¹é, ¾ÆÀÌÆ®·¡Å·, »ýüÀÎ½Ä ¸ð´ÏÅ͸µÀº Âü¿©µµ¸¦ ÃøÁ¤ÇÏ°í °³ÀÔÀ» µ¿ÀûÀ¸·Î Á¶Á¤Çϱâ À§ÇØ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù.

¸Ó½Å·¯´× ¸ðµ¨ÀÌ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© °³ÀÔÀÇ °­µµ, ±â°£, º¹À⼺À» ÃÖÀûÈ­ÇÏ¿© »ç¿ëÀÚ°¡ ÀûÀýÇÑ '¾ç'ÀÇ µðÁöÅÐ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. Áõ°­Çö½Ç(AR)°ú °¡»óÇö½Ç(VR) ÀÎÅÍÆäÀ̽º´Â ƯÈ÷ ºÒ¾È°¨ °¨¼Ò¿Í °øÆ÷Áõ Å»°¨ÀÛÀ» À§ÇØ ¸ôÀÔ°¨°ú È¿°ú¼ºÀ» ³ôÀ̱â À§ÇØ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀϺΠÇ÷§ÆûÀº ¿þ¾î·¯ºí°ú ÅëÇÕµÇ¾î ½É¹Ú¼ö º¯µ¿ ¹× °¥¹Ù´Ð ÇǺΠ¹ÝÀÀ°ú °°Àº ½ºÆ®·¹½º ¸¶Ä¿¸¦ ¸ð´ÏÅ͸µÇÏ¿© µðÁöÅÐ ¹é½Å ¼¼¼ÇÀÇ ÀÎÁö ºÎÇÏ ¹× ¹ÝÀÀ ÇÁ·ÎÆÄÀÏÀ» Á¶Á¤ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

µðÁöÅÐ ¹é½Å ±â¼ú äÅÃÀ» ÃËÁøÇÏ´Â ÃÖÁ¾ »ç¿ë ºÐ¾ß´Â?

±³À° ºÐ¾ß, ƯÈ÷ K-12 ¹× À¯¾Æ ±³À° ÇÁ·Î±×·¥Àº ¾ÆÀ̵éÀÇ Á¤¼­Àû Áö´É, ÀÚ±âÁ¶Àý ´É·Â ¹× »çȸÀû ÀûÀÀ·ÂÀ» Çâ»ó½Ã۱â À§ÇØ µðÁöÅÐ ¹é½ÅÀ» °¡Àå Àû±ØÀûÀ¸·Î äÅÃÇϰí ÀÖ´Â ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ÇнÀ Ä¿¸®Å§·³¿¡ ÅëÇյǰųª µ¶¸³Çü ¿ëµµÀ¸·Î ¹èÆ÷µÇ¾î ƯÈ÷ »óó¹Þ±â ½¬¿î »ç¶÷À̳ª Æ®¶ó¿ì¸¶¿¡ ¿µÇâÀ» ¹ÞÀº »ç¶÷µéÀÇ ½É¸®Àû Áغñ ż¼¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¼Ò¾Æ°ú ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ADHD, Çൿ Ä¡·á, ÀÚÆóÁõ ½ºÆåÆ®·³¿¡ ´ëÇÑ °³ÀÔÀÇ º¸Á¶ ¼ö´ÜÀ¸·Î µðÁöÅÐ ¹é½ÅÀ» °í·ÁÇϰí ÀÖ½À´Ï´Ù.

±â¾÷ À£´Ï½º ¹× Á¤½Å°Ç°­ ÇÁ·Î±×·¥¿¡¼­ µðÁöÅÐ ¹é½ÅÀº Á÷¿øµéÀÇ ¼ÒÁøÀ» ¿ÏÈ­Çϰí, ÀÎÁö ±â´ÉÀ» °³¼±Çϸç, Á¤¼­Àû ȸº¹·ÂÀ» ÈÆ·ÃÇϱâ À§ÇØ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛ°ú º¸Çè»çµéÀº ƯÈ÷ °íÀ§Ç豺 Áý´Ü¿¡¼­ ºñÀÓ»ó ¿¹¹æ Ä¡·á·Î ÀÌ·¯ÇÑ ÅøÀ» Æò°¡Çϱ⠽ÃÀÛÇß½À´Ï´Ù. µðÁöÅÐ Ä¡·á ±â¾÷°ú ½Å°æ°úÇÐ ½ºÅ¸Æ®¾÷µéÀº ¾à¹° ³²¿ë, ¿ì¿ïÁõ, ¸¸¼º ½ºÆ®·¹½º¿Í °°Àº ¹®Á¦¿¡ ´ëÇÑ º´Å»ý¸®ÇÐÀû ¹é½ÅÀ» Ãâ½ÃÇϸç ÇൿÀÇÇп¡¼­ µðÁöÅÐ °Ç°­ÀÇ ¿ªÇÒÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.

µðÁöÅÐ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

µðÁöÅÐ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº È®Àå °¡´ÉÇÑ Á¤½Å°Ç°­ °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ºñ¾à¹°Àû ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ë È®´ë, ÀÎÁö °Ç°­ Ç÷§Æû¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¸ðµç ¿¬·É´ë¿¡¼­ Á¤½ÅÀå¾Ö, »ýȰ½À°üÀ¸·Î ÀÎÇÑ °Ç°­ ¹®Á¦, Çൿ À§Çè ¿äÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤ºÎ¿Í °í¿ëÁÖµéÀº Á¢±ÙÀÌ ¿ëÀÌÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» ã°í ÀÖ½À´Ï´Ù.

¸ð¹ÙÀÏ °Ç°­ ¾ÛÀÇ È®»ê, À£´Ï½º ÇÁ·Î±×·¥¿¡¼­ÀÇ Çൿ AI µµÀÔ Áõ°¡, µðÁöÅÐ Ä¡·áÁ¦ÀÇ ÀÓ»ó Ä¡·á·ÎÀÇ ÅëÇÕ, ±³À° ÇöÀå¿¡¼­ÀÇ °¨Á¤ ÇнÀ¿¡ ´ëÇÑ Á߿伺 È®´ë µî ÃÖÁ¾»ç¿ëÀÚ µ¿ÇâÀÌ Ã¤Åÿ¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Å°æ°úÇÐ, Çൿ°úÇÐ, µðÁöÅÐ ±â¼úÀÇ À¶ÇÕÀº µðÁöÅÐ ¹é½ÅÀÇ È¿´ÉÀ» Áö¼ÓÀûÀ¸·Î °³¼±ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ÇコÄɾ °³ÀÎÈ­µÈ »çÀü ¿¹¹æÀû Ä¡·á ¸ðµ¨·Î ÀüȯÇÏ´Â °¡¿îµ¥, µðÁöÅÐ ¹é½ÅÀº ÀÎÁö°úÇаú µðÁöÅÐ Á¢±Ù¼ºÀ» °áÇÕÇÏ¿© Á¤½ÅÀû, ÇൿÀû À£ºùÀ» º¸È£ÇÏ´Â ¼¼°è °Ç°­ ¿¹¹æ ÅøÅ°Æ®ÀÇ Áß¿äÇÑ °èÃþÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

µð¹ÙÀ̽º(½º¸¶Æ®Æù µð¹ÙÀ̽º, ÅÂºí¸´ µð¹ÙÀ̽º, ±âŸ µð¹ÙÀ̽º); ¾ÖÇø®ÄÉÀ̼Ç(´ç´¢º´ ¾ÖÇø®ÄÉÀ̼Ç, °¨¿°Áõ ¾ÖÇø®ÄÉÀ̼Ç, ½ÉÇ÷°üÁúȯ ¾ÖÇø®ÄÉÀ̼Ç, ±âŸ ¾ÖÇø®ÄÉÀ̼Ç)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 34°Ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Digital Vaccines Market to Reach US$3.1 Billion by 2030

The global market for Digital Vaccines estimated at US$1.8 Billion in the year 2024, is expected to reach US$3.1 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Smartphones Device, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Tablets Device segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$496.5 Million While China is Forecast to Grow at 12.7% CAGR

The Digital Vaccines market in the U.S. is estimated at US$496.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$627.8 Million by the year 2030 trailing a CAGR of 12.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Digital Vaccines Market - Key Trends & Drivers Summarized

What Are Digital Vaccines and Why Are They Redefining Preventive Healthcare?

Digital vaccines represent a new paradigm in preventive health, utilizing digital platforms and neurocognitive training to influence behavior, boost resilience, and strengthen immunity against disease-not through biological agents, but via behavioral conditioning and neural modulation. Delivered via smartphones, tablets, or virtual reality systems, digital vaccines are software-based interventions that engage users in structured exercises designed to prevent conditions such as stress, anxiety, addiction, or even infectious diseases by altering behavior and improving mental and physiological response patterns.

Unlike conventional vaccines that stimulate an immune response through antigens, digital vaccines operate by activating brain circuits to train the nervous system and enhance behavioral immunity. These solutions are especially relevant in tackling mental health disorders, behavioral dependencies, and lifestyle diseases. In children, for example, digital vaccines are being developed to promote social-emotional learning and cognitive skills to reduce susceptibility to anxiety or peer pressure-induced behaviors. In adults, these tools aim to condition stress responses, reduce smoking or drinking habits, and promote cognitive resilience.

Which Technologies Are Powering the Emergence of Digital Vaccine Platforms?

Digital vaccines rely on an array of cognitive computing technologies, including artificial intelligence, gamification, neurobehavioral algorithms, and adaptive learning models. Mobile applications serve as the primary delivery interface, while AI is used to customize cognitive tasks based on the user’s behavioral data and performance patterns. Neurofeedback, eye tracking, and biometric monitoring are also being incorporated to measure engagement and tailor interventions dynamically.

Machine learning models analyze real-time data to optimize intervention intensity, duration, and complexity, ensuring that users receive the right “dose” of digital therapy. Augmented reality (AR) and virtual reality (VR) interfaces are being used to enhance immersion and efficacy, particularly for anxiety reduction or phobia desensitization. Some platforms integrate with wearables to monitor stress markers like heart rate variability or galvanic skin response, which helps in calibrating the cognitive load and response profile of the digital vaccine session.

Which End-Use Segments Are Driving Adoption of Digital Vaccine Technologies?

The education sector, especially K-12 and early childhood programs, is one of the most active adopters of digital vaccines, using them to build emotional intelligence, self-regulation, and social adaptability among children. These tools are embedded into learning curriculums or deployed as standalone applications to improve psychological readiness, particularly in vulnerable or trauma-affected populations. Pediatric healthcare providers are exploring digital vaccines as adjuncts to ADHD, behavioral therapy, and autism spectrum interventions.

In corporate wellness and mental health programs, digital vaccines are gaining popularity to mitigate burnout, improve cognitive function, and train emotional resilience among employees. Healthcare systems and insurers are beginning to evaluate these tools for non-clinical preventive care, particularly in high-risk populations. Digital therapeutics firms and neuroscience startups are also launching condition-specific vaccines for issues like substance abuse, depression, and chronic stress, expanding the role of digital health in behavioral medicine.

What Factors Are Driving the Growth of the Digital Vaccines Market?

The growth in the digital vaccines market is driven by several factors, including the increasing need for scalable mental health interventions, growing acceptance of non-pharmaceutical preventive care, and rising investment in cognitive health platforms. The rising burden of mental disorders, lifestyle-induced health problems, and behavioral risk factors across all age groups is pushing governments and employers to seek accessible and cost-effective solutions-something digital vaccines are well-positioned to offer.

End-use trends such as the proliferation of mobile health apps, the rising deployment of behavioral AI in wellness programs, integration of digital therapeutics into clinical care, and expanding emphasis on emotional learning in educational settings are fueling adoption. Moreover, the convergence of neuroscience, behavioral science, and digital technology is enabling continuous refinement of digital vaccine efficacy. As healthcare shifts toward personalized and proactive care models, digital vaccines are emerging as a vital layer in the global health prevention toolkit-blending cognitive science with digital accessibility to protect mental and behavioral well-being.

SCOPE OF STUDY:

The report analyzes the Digital Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Device (Smartphones Device, Tablets Device, Other Devices); Application (Diabetes Application, Infectious Diseases Application, Cardiovascular Diseases Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â